Trial · NCT07912606
D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
NCT07912606, Phase 2, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer. Trials, record NCT07912606. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912606
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
- NCT number
- NCT07912606
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 32 participants, estimated
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Gastrectomy with D2 lymphadenectomy plus para-aortic lymph node dissection, Gastrectomy with standard D2 lymphadenectomy
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival rate at 2 years | From randomization to 2 years after randomization | Progression-free survival is measured from randomization to the earliest of radiologic or clinical disease progression, postoperative local, regional, or distant recurrence, or death from any cause. Participants without an event are censored at the date of their last adequate disease assessment. The 2-year progression-free survival rate will be estimated by the Kaplan-Meier method. |
| Secondary | Recurrence-free survival rate at 2 years after surgery | From surgery to 2 years after surgery | Among participants who undergo R0 resection, recurrence-free survival is measured from surgery to the earliest of local, regional, or distant recurrence or death from any cause. Participants without an event are censored at the date of their last adequate disease assessment. |
| Secondary | Overall survival | From randomization through 5 years after surgery | Overall survival is measured from randomization to death from any cause. Participants alive at the last follow-up are censored on that date. |
| Secondary | Cumulative incidence of para-aortic lymph node region recurrence | From randomization through 5 years after surgery | Recurrence involving the No. 16a2 or No. 16b1 region is determined by imaging, pathology, or clinical evidence. The cumulative incidence will be estimated with death without para-aortic recurrence treated as a competing event, and recurrence patterns will be summarized. |
| Secondary | R0 resection rate | At definitive postoperative pathological assessment, generally within 30 days after surgery | The percentage of randomized participants with microscopically negative proximal, distal, and applicable circumferential or other resection margins. |
| Secondary | Pathological complete response rate | At definitive postoperative pathological assessment, generally within 30 days after surgery | The percentage of participants with no residual viable tumor in the gastric primary tumor and all evaluated lymph nodes, defined as ypT0N0. |
| Secondary | Number of examined and metastatic regional lymph nodes | At definitive postoperative pathological assessment, generally within 30 days after surgery | Regional lymph nodes will be recorded by station, including the number examined and the number with pathologically confirmed metastasis. |
| Secondary | Pathological positivity rate of No. 16 para-aortic lymph nodes in the experimental arm | At definitive postoperative pathological assessment, generally within 30 days after surgery | Among participants assigned to D2 lymphadenectomy plus para-aortic lymph node dissection who have an evaluable No. 16 specimen, the percentage with at least one pathologically metastatic No. 16 lymph node and the numbers examined and metastatic will be reported. |
| Secondary | Operative time | During the assigned surgery | Operative time in minutes, measured according to the institutional anesthesia and operative record, will be summarized by randomized group. |
| Secondary | Estimated intraoperative blood loss | During the assigned surgery | Estimated blood loss in milliliters, as recorded in the operative and anesthesia records, will be summarized by randomized group. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912606
GET https://conductscience.org/api/trials/v1/NCT07912606/registered